TECK/CCL25 蛋白, Human

TECK/CCL25 Protein, Human is a CC chemokine that binds to the chemokine receptor CCR9 and is involved in the development of T cells and cell migration to the small intestine, as well as a variety of inflammatory diseases and promotes inflammatory responses. It has chemotactic effects on thymocytes, macrophages and dendritic cells. TECK/CCL25 Protein, Human is a recombinant human TECK/CCL25(Q24-L150) protein expressed byE. coli^[1][2].

CCL25，也称为表达胸腺的趋化因子TECK，是CC趋化因子家族的一种小细胞因子，位于人类基因组的19号染色体上。CCL25主要表达于胸腺和肠上皮，但也可由血管内皮细胞等实质细胞产生，可将未成熟的T细胞迁移至胸腺成熟释放。它对胸腺细胞、巨噬细胞和树突状细胞具有趋化作用，并可与趋化因子受体 CCR9 联合作用。其中，CCR9被发现是一种G蛋白偶联受体，表达在树突状细胞、中性粒细胞、淋巴细胞、单核巨噬细胞和血管内皮细胞的细胞膜上。CCR9属于β-趋化因子受体家族，该基因位于3号染色体上的p21.31。CCL25-CCR9 参与 T 细胞的发育和细胞向小肠的迁移，以及多种炎症性疾病并促进炎症反应，包括心血管疾病 (CVD)、肝炎和关节炎。CCL25 与 CCR9 的相互作用还通过 Akt/蛋白激酶 B 激活抑制细胞凋亡，支持胸腺成熟期间 T 细胞的存活^[1][2]。

CCL25 (100 ng/mL) can induce migration and invasion in human OvCa cell lines that are CCR9-dependent. It causes OVCAR-3 cells to significantly express MMP-8 and MMP-13 mRNA and MMP-1 and -8 active proteins, resulting in a selective but significant increase in active MMP-3 and -10 secretion by CAOV-3 cells^[3].
CCL25 (100 ng/mL) significantly enhances the growth of human BrCa cell lines MDA-MB-231 cells and protects against cisplatin (<5 μg/mL)-mediated growth inhibition. CCL25-mediated protection against cisplatin-induced growth inhibition of BrCa cells disappears as cisplatin concentrations reached ≥10 μg/mL. It also significantly reduces the percentage of apoptotic cells treated with cisplatin^[4].

Full biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration range of 1.0-10 ng/ml.

Human

E. coli

Tag Free

O15444 (Q24-L150)

6370  [NCBI]

MQGVFEDCCLAYHYPIGWAVLRRAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDARNKVFAKLHHNTQTFQAGPHAVKKLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL

Approximately 14.3 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized after extensive dialysis against 20 mM PB, pH 7.4, 150 mM NaCl.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Marcus Svensson, et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest. 2002 Oct;110(8):1113-21.  [Content Brief]

  [2]. Xue Wu, et al. The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Front Cell Dev Biol. 2021 Aug 19;9:686548.  [Content Brief]

  [3]. Erica L Johnson, et al. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22;8:62.  [Content Brief]

  [4]. Crystal Johnson-Holiday, et al. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 3;9:46.  [Content Brief]